< 800
Within reference range
Low likelihood of disease activity
AIH cohort: Likely quiescent disease A,B,C,D
800-874>
Elevated
Elevated levels of disease activity
Increased risk of cardiovascular and/or liver related hospitalizations E,F
MASLD cohort: Probable MASH G
AIH cohort: Increased risk of flare/relapse and/or ongoing disease activity A,B,C,D
≥ 875
Highly elevated
Highly elevated levels of disease activity
Increased risk of cardiovascular and/or liver related hospitalizations E,F
Additional increased risk of liver related outcomes F
MASLD cohort: Probable at-risk MASH G
AIH cohort: Increased risk of flare/relapse and/or ongoing disease activity A,B,C,D
AIH: Autoimmune hepatitis
MASLD: Metabolic dysfunction-associated steatolic liver disease (previously known as non-alcoholic fatty liver disease, NAFLD)
MASH: Metabolic dysfunction-associated steatohepatitis (previously known as non-alcoholic steatohepatitis, NASH)
At-risk MASH: Steatohepatitis with significant fibrosis; higher risk of liver-related morbidity and mortality H
Liver related outcomes include: liver cirrhosis, esophageal varices, gastric varices, hepatorenal syndrome, ascites, portal hypertension, hepatocellular carcinoma, liver failure, liver transplant, liver related hospitalization F
Arndtz K, Shumbayawonda E, Hodson J, Eddowes PJ, Dennis A, Thomaides-Brears H, Mouchti S, Kelly MD, Banerjee R, Neubauer S, Hirschfield GM | Multiparametric MRI imaging, autoimmune hepatitis, and prediction of disease activity | Hepatology Communications (2021)
Heneghan MA, Shumbayawonda E, Dennis A, Ahmed RZ, Rahim MN, Ney M, Smith L, Kelly M, Banerjee R, Culver EL | Quantitative Magnetic Resonance Imaging to Aid Clinical Decision Making in Autoimmune Hepatitis | EClinicalMedicine (2022)
Janowski K, Shumbayawonda E, Cheng L, Langford C, Dennis A, Kelly M, Pronicki M, Grajkowska W, Wozniak M, Pawliszak P, Chełstowska S, Jurkiewicz E, Banerjee R, Socha P | Quantitative multiparametric MRI as a non-invasive stratification tool in children and adolescents with autoimmune liver disease | Scientific Reports (2021)
Trout AT, Taylor AE, Kasten JL, Castro-Rojas C, Mahalingam N, Miethke AG, Dillman JR | Corrected T1 mapping in children and young adults with autoimmune liver disease: Correlation with histology | American Journal of Roentgenology (2023)
Roca-Fernandez A, Banerjee R, Thomaides-Brears H, Telford A, Sanyal A, Neubauer S, Nichols TE, Raman B, McCracken C, Petersen SE, Ntusi NA, Cuthbertson DJ, Lai M, Dennis A, Banerjee A | Liver disease is a significant risk factor for cardiovascular outcomes | JHEP Reports (2023)
Jackson E, Dennis A, Alkhouri N, Samala N, Vuppalanchi R, Sanyal AJ, Muthiah M, Banerjee R, Banerjee A. | Cardiac and liver impairment on multi-organ MRI and risk of major adverse cardiovascular and liver events | Nature Medicine (2025)
Andersson A, Kelly M, Imajo K, Nakajima A, Fallowfield JA, Hirschfield G, Pavlides M, Sanyal AJ, Noureddin M, Banerjee R, Dennis A, Harrison S | Clinical utility of MRI biomarkers for identifying NASH patients at high risk of progression: A multi-center pooled data and meta-analysis | Clinical Gastroenterology and Hepatology (2021)
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE, Loomba R | AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease | Hepatology (2023)